Dextroamphetamine/Amphetamine
Brand names: Adderall Xr, Dextroamphetamine-Amphet Er, Mydayis, Adderall, Dextroamphetamine-Amphetamine
Part of: ADHD stimulants
At a glance
- Medicare prescriptions, 2024
- 1,913,854
- Medicare drug cost
- $75.9M
- Average cost per prescription
- $39.64
- Clinicians who prescribed it
- 51,667
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release Capsules, a CNS stimulant, are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Limitations of Use The use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: ABUSE, MISUSE, and ADDICTION Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 29.3%
- Family Medicine 19.8%
- Psychiatric Nurse Practitioners 17.8%
- Internal Medicine 10.1%
- Nurse Practitioners 8.9%
- Physician Assistants 5.1%
- Neurology 3.1%
- Child & Adolescent Psychiatry 1.9%
- General Practice 0.5%
- Pulmonology 0.5%
- Sleep Medicine 0.5%
- Addiction Medicine 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 30% from 2019 to 2024.
Biggest change by state since 2019
- Idaho +59%
- Iowa +52%
- Kentucky +50%
- Montana +49%
- Kansas +46%
- Maine (smallest change) +5%
- Massachusetts (smallest change) +8%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amneal Pharmaceuticals of New York LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1.25 mg / 1.25 mg amphetamine aspartate monohydrate / 1.25 mg dextroamphetamine sulfate / 1.25 mg amphetamine sulfate | turquoise capsule, 16 mm | G451 |
| 2.5 mg / 2.5 mg amphetamine aspartate monohydrate / 2.5 mg dextroamphetamine sulfate / 2.5 mg amphetamine sulfate | turquoise capsule, 16 mm | G452 |
| 3.75 mg / 3.75 mg amphetamine aspartate monohydrate / 3.75 mg dextroamphetamine sulfate / 3.75 mg amphetamine sulfate | white capsule, 18 mm | G453 |
| 5 mg / 5 mg amphetamine aspartate monohydrate / 5 mg dextroamphetamine sulfate / 5 mg amphetamine sulfate | brown capsule, 18 mm | G454 |
| 6.25 mg / 6.25 mg amphetamine aspartate monohydrate / 6.25 mg dextroamphetamine sulfate / 6.25 mg amphetamine sulfate | white capsule, 21 mm | G455 |
| 7.5 mg / 7.5 mg amphetamine aspartate monohydrate / 7.5 mg dextroamphetamine sulfate / 7.5 mg amphetamine sulfate | brown capsule, 21 mm | G456 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Jun 2026 · Lannett Company Inc. · Class II
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules. - Aug 2025 · Granules Pharmaceuticals Inc. · Class III
Failed Impurities/Degradation Specifications: - Oct 2020 · Ani Pharmaceuticals, Inc. · Class III
Labeling: Incorrect expiration date. Product dated with 24-month expiration date instead of 18-months.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.